论文部分内容阅读
应用基因重组人红细胞生成素（ｒＨｕＥＰＯ）治疗４０例慢性血液透析（ＣＨＤ）患者的贫血。在起始治疗阶段分为皮下注射和静脉注射两组，皮下注射的平均剂量为每周１７５Ｕｋｇ－１，静脉注射的平均剂量为每周２８２Ｕｋｇ－１。治疗前两组之间的血红蛋白（Ｈｂ）和血细胞比容（ＨＣｔ）值近似，治疗８周后两组病人的Ｈｂ和Ｈｃｔ都有显著上升，静脉注射组上升幅度更大，但两组之间差异无统计学意义。皮下注射的副作用仅为静脉注射的１６．７％，且程度较轻。结果提示，皮下注射ｒＨｕＥＰＯ治疗ＣＨＤ贫血与静脉注射同样有效，而且更加经济安全。
Treatment of anemia in 40 patients with chronic hemodialysis (CHD) using gene recombinant human erythropoietin (rHuEPO). The initial treatment period was divided into subcutaneous injection and intravenous injection, the average dose of subcutaneous injection 175Ukg-1 per week, the average intravenous dose of 282Ukg-1 per week. Hb and HCT values were similar between the two groups before treatment, and Hb and Hct were significantly increased in both groups after 8 weeks of treatment, with a greater increase in the intravenous group, but between the two groups The difference was not statistically significant. The side effects of subcutaneous injection is only 16.7% of intravenous injection, and to a lesser extent. The results suggest that subcutaneous rHuEPO treatment of CHD anemia and intravenous injection are equally effective, but also more economical and safe.